Get the Stockscreener App
4.4199
6.88%
0.3499
Minerva Neurosciences Inc stock is traded at $4.4199, with a volume of 47,217.
It is up +6.88% in the last 24 hours and up +3.82% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$4.07
Open:
$4.04
24h Volume:
47,217
Relative Volume:
0.29
Market Cap:
$185.30M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.9932
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
-0.46%
1M Performance:
+3.82%
6M Performance:
+104.23%
1Y Performance:
+83.54%
1-Day Range:
$3.954
$4.45
1-Week Range:
$3.75
$4.65
52-Week Range:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.2819 | 176.13M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.70 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.66 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
868.02 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.68 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.25 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences to Host Virtual KOL Event to Discuss - GlobeNewswire
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Highs Report: Is Minerva Neurosciences Inc trading at a discountJuly 2025 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Earnings Update: Can Minerva Neurosciences Inc stock double in the next yearFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
FOMO Trade: Will Minerva Neurosciences Inc benefit from seasonalityJuly 2025 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
Downgrade Watch: Can Minerva Neurosciences Inc stock reach 100 price targetWeekly Investment Summary & Stepwise Trade Signal Guides - Bộ Nội Vụ
Gap Down: Will Minerva Neurosciences Inc 4MNA stock top growth indexes - Bộ Nội Vụ
Street Watch: Is Minerva Neurosciences Inc stock a top pick in earnings seasonVolume Spike & Real-Time Stock Movement Alerts - Bộ Nội Vụ
Wall Street Recap: Why analysts upgrade Minerva Neurosciences Inc. stock2025 Key Highlights & Verified Short-Term Trading Plans - Bộ Nội Vụ
Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street Zen - MarketBeat
What risks investors should watch in Minerva Neurosciences Inc. stockWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Minerva Neurosciences Inc. (4MNA) stock attractive for dividend growth2025 Trading Volume Trends & Long-Term Capital Growth Strategies - Улправда
Is Minerva Neurosciences Inc. stock attractive for hedge fundsJuly 2025 Technicals & Real-Time Buy Signal Notifications - Улправда
Why Minerva Neurosciences Inc. stock is in analyst buy zone2025 Analyst Calls & Long-Term Investment Growth Plans - Улправда
Is Minerva Neurosciences Inc. stock safe for conservative investorsJuly 2025 Retail & Reliable Trade Execution Plans - Улправда
Why Minerva Neurosciences Inc. stock is rated strong buyJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Will Minerva Neurosciences Inc. (4MNA) stock top growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Улправда
Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis - Defense World
Working capital per share of Minerva Neurosciences Inc – MUN:4MNA - TradingView — Track All Markets
Gains Recap: Why Minerva Neurosciences Inc stock is in analyst buy zoneProduct Launch & Free Expert Verified Stock Movement Alerts - moha.gov.vn
MSN Money - MSN
Published on: 2025-12-26 01:20:46 - moha.gov.vn
Reviewing Xenetic Biosciences (NASDAQ:XBIO) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences shareholders approve key governance measures - MSN
Minerva Neurosciences Shareholders Approve Key Governance Measures - TipRanks
Risks Report: Why Minerva Neurosciences Inc. (4MNA) stock stays resilientMarket Activity Summary & Free High Accuracy Swing Entry Alerts - Улправда
Movement Recap: Why analysts upgrade Minerva Neurosciences Inc. stock2025 Growth vs Value & AI Powered Market Entry Ideas - Улправда
How strong is Minerva Neurosciences Inc. stock revenue growthGold Moves & Weekly High Return Forecasts - Улправда
Why analysts upgrade Minerva Neurosciences Inc. stockIndex Update & Risk Controlled Swing Alerts - Улправда
Inderjit Kaul Net Worth (2025) - GuruFocus
Minerva Neurosciences (NERV) Price Target Increased by 12.50% to 4.59 - Nasdaq
Is Minerva Neurosciences Inc. stock a buy for dividend growth2025 EndofYear Setup & Safe Entry Zone Tips - Newser
How risky is Minerva Neurosciences Inc. (4MNA) stock compared to peersPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
How Minerva Neurosciences Inc. stock reacts to oil prices2025 Top Decliners & Technical Pattern Recognition Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Is Minerva Neurosciences Inc. stock attractive for retirement portfolios2025 Earnings Surprises & Capital Efficiency Focused Strategies - Newser
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Will Minerva Neurosciences Inc. (4MNA) stock boost dividends furtherSell Signal & Fast Exit and Entry Strategy Plans - Newser
Is Minerva Neurosciences Inc. (4MNA) stock cheap vs fundamentalsJuly 2025 Action & Verified Swing Trading Watchlist - Newser
Minerva Neurosciences (NERV) Stock Analysis Report | Financials & Insights - Benzinga
How Minerva Neurosciences Inc. (4MNA) stock compares with tech leadersJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Market Fear: Why Minerva Neurosciences Inc 4MNA stock stays resilientJuly 2025 Outlook & Capital Efficiency Focused Ideas - moha.gov.vn
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):